Your Evidence-Based Guide to Semaglutide & GLP-1 Therapy
Semaglutide Guide is the UK’s leading independent editorial resource for clinically rigorous, clearly explained information on GLP-1 receptor agonists, weight management pharmacology, and therapeutic peptides. Written for patients, reviewed by clinicians.
with tirzepatide (SURMOUNT)
STEP trial follow-up
worldwide (WHO, 2024)
Why Evidence-Based Information Has Never Mattered More
We are living through a genuine revolution in the pharmacological treatment of obesity and metabolic disease. For decades, weight management medicine was characterised by modest results, high relapse rates, and a persistent — and scientifically unfounded — cultural assumption that body weight is primarily a matter of willpower. The arrival of GLP-1 receptor agonists as weight management treatments has demolished that assumption and forced a wholesale reassessment of how medicine understands, researches, and treats excess adiposity.
Semaglutide, the active ingredient in Ozempic and Wegovy, became one of the fastest-selling pharmaceutical products in history following its approval for weight management. Tirzepatide (Mounjaro), the dual GIP/GLP-1 agonist, has produced results in clinical trials that rival bariatric surgery. These are not marginal improvements on existing treatments — they represent a step change in efficacy that has captured the attention of clinicians, health economists, insurers, health systems, and the general public in equal measure.
But the speed and scale of this revolution has also created significant risks. When demand outstrips supply — as it has repeatedly for both Ozempic and Wegovy — it creates fertile conditions for counterfeit products, unlicensed compounding operations, and online misinformation. Social media platforms have become saturated with anecdotal accounts, promotional content from commercial providers, and claims that range from misleading to outright dangerous. The signal-to-noise ratio for a patient trying to make an informed decision about GLP-1 therapy has never been lower.
This is why Semaglutide Guide exists. We believe that the extraordinary clinical advances in GLP-1 pharmacology deserve an equally serious editorial response — one that treats patients as intelligent adults capable of engaging with the evidence when it is presented clearly, contextualised honestly, and updated regularly. We do not accept advertising from pharmaceutical companies or weight loss services. We do not receive payments for placement or favourable coverage. Our editorial standards require that every clinical claim be traceable to peer-reviewed evidence or authoritative regulatory guidance.
The guides on this site cover the full spectrum of GLP-1 and peptide therapy: from the basic pharmacology of the incretin system to practical guidance on managing side effects, from a detailed examination of the STEP and SURMOUNT trial datasets to a sober look at the emerging evidence on therapeutic peptides. Whether you are a patient considering GLP-1 therapy for the first time, a healthcare professional looking for clearly synthesised evidence summaries, or a researcher interested in the evolving landscape of metabolic pharmacology, you will find this resource useful. We are committed to building the most reliable, comprehensive, and editorially independent GLP-1 resource available to UK audiences.
What You Will Find Here
Our content is organised into three core knowledge areas, each curated to serve a different stage of your GLP-1 journey.
Semaglutide Basics
New to semaglutide? Start here. Our foundational guides explain what semaglutide is, how it works in the body, the difference between Ozempic and Wegovy, what to expect in the first weeks of treatment, how to manage common side effects, and the clinical data behind the drug’s impressive weight loss outcomes. We cover the full escalation protocol, injection technique, storage requirements, and what happens when you stop treatment. These guides are written for a general audience and do not require prior medical knowledge — but they are grounded in the same clinical evidence base used by specialist prescribers.
GLP-1 Medications
The GLP-1 receptor agonist class now encompasses a wide range of molecules, delivery methods, and approved indications. Our GLP-1 medications hub provides comprehensive coverage of every agent in the class — from the established once-daily liraglutide to the revolutionary dual-agonist tirzepatide and the anticipated next-generation compounds currently in clinical development. We cover mechanisms, trial results, comparative efficacy, approved indications, regulatory status in the UK, and practical considerations for patients choosing between options. We also track emerging oral GLP-1 formulations and the pipeline of compounds approaching regulatory approval.
Peptide Therapy
Beyond the GLP-1 drug class, a broader world of therapeutic peptides has attracted intense scientific and patient interest. Our peptide therapy guides provide the most thorough, evidence-based English-language review available of compounds including BPC-157, TB-500 (thymosin beta-4), CJC-1295, Ipamorelin, and others. We approach this subject with the same rigour we apply to licensed medications — meaning we distinguish clearly between established animal model data, preliminary human evidence, and speculative claims, and we address the regulatory status of each compound in the UK honestly and without commercial motivation.
Understanding GLP-1 Medications: How They Work
To understand why GLP-1 receptor agonists are so effective, it helps to understand the biological system they are designed to engage. The gut-brain axis — the complex bidirectional communication network between the gastrointestinal tract and the central nervous system — plays a far more sophisticated role in regulating appetite, energy expenditure, and metabolic function than was recognised until relatively recently. GLP-1 receptor agonists work by mimicking and amplifying signals within this system that are naturally produced after a meal.
The Incretin Effect
The term “incretin” refers to a class of gut-derived hormones that stimulate insulin secretion in response to nutrient ingestion. The two principal incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Under normal physiological conditions, GLP-1 is secreted by L-cells in the distal small intestine and colon within minutes of food entering the gut. Its natural half-life is just 1–2 minutes before it is broken down by the enzyme DPP-4.
This is known as the incretin effect — the observation that oral glucose administration produces a substantially greater insulin response than intravenous glucose administration, because the oral route triggers incretin secretion whilst the intravenous route does not. In people with type 2 diabetes, this incretin effect is markedly diminished, contributing to insufficient insulin secretion and postprandial hyperglycaemia.
Appetite Regulation and Metabolic Effects
GLP-1 exerts its effects through receptors distributed throughout the body, but for weight management the most important sites are in the central nervous system — particularly the hypothalamus and brainstem. Activation of GLP-1 receptors in the hypothalamic arcuate nucleus reduces the activity of appetite-stimulating neurons (NPY/AgRP neurons) and increases the activity of appetite-suppressing neurons (POMC neurons). In the brainstem, GLP-1 receptor activation reinforces satiety signals from the gut and modulates the reward value of food.
Pharmacologically engineered GLP-1 receptor agonists circumvent the drug’s natural 1–2 minute half-life through structural modifications that resist DPP-4 degradation. Semaglutide, for instance, has a half-life of approximately 7 days — achieved through a fatty acid chain that binds reversibly to albumin in the bloodstream, effectively acting as a depot that slowly releases the active drug. This extended half-life enables once-weekly dosing and produces continuous, stable GLP-1 receptor activation that far exceeds what the body produces endogenously.
Beyond Appetite: Broader Metabolic Benefits
The clinical benefits of GLP-1 receptor agonists extend well beyond appetite suppression. Semaglutide demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in the SUSTAIN-6 trial and a 20% reduction in the SELECT trial — which was specifically powered to test cardiovascular outcomes in non-diabetic obese patients. Emerging research also suggests benefits in non-alcoholic steatohepatitis (NASH), polycystic ovarian syndrome (PCOS), sleep apnoea, and — most intriguingly — early-stage neurodegeneration. The full therapeutic scope of GLP-1 receptor agonism is still being characterised.
“The advent of highly effective anti-obesity medications represents a turning point in medicine — one that compels us to reconceptualise obesity as a complex, chronic, relapsing disease amenable to pharmacological management.”
— The Lancet Diabetes & Endocrinology, 2023 Special Report on GLP-1 Pharmacology
Semaglutide Deep Dive: History, Development & Evidence
Semaglutide is a synthetic analogue of human GLP-1 developed by Novo Nordisk and first approved for the treatment of type 2 diabetes in 2017. Its discovery followed decades of research into the incretin system that began in earnest in the 1980s with the identification of GLP-1 as a potent insulin secretagogue. The journey from that foundational science to one of the best-selling pharmaceutical products in history is a story of disciplined drug development, unexpected discoveries about the drug’s effect on body weight, and a regulatory pathway shaped by the cardiovascular safety requirements imposed following the rosiglitazone scandal of 2007.
Foundational science: GLP-1 identified as an incretin hormone. Researchers establish its role in glucose-dependent insulin secretion and begin exploring synthetic analogues.
First GLP-1 agonist approved: Exenatide (Byetta) receives FDA approval for type 2 diabetes — the first GLP-1 receptor agonist in clinical use.
Semaglutide (Ozempic) approved: Weekly injectable semaglutide achieves regulatory approval for type 2 diabetes in the US and Europe. SUSTAIN trial programme demonstrates superior efficacy to other agents in the class.
STEP trials report: The STEP 1–5 trial programme demonstrates semaglutide 2.4mg (Wegovy) produces an average 15–17% reduction in body weight over 68 weeks in people without diabetes. Wegovy approved by MHRA for UK use in 2023.
SELECT trial results: Semaglutide demonstrates a 20% reduction in major adverse cardiovascular events in people with obesity but without diabetes — a landmark result that reshapes how cardiologists think about weight management.
NHS rollout and supply constraints: NHS England begins expanding access to Wegovy through specialist weight management services. Supply shortfalls continue to affect availability. Oral semaglutide (Rybelsus) gains broader traction in type 2 diabetes management.
The STEP Trials: What the Evidence Shows
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme comprised five large randomised controlled trials examining the efficacy and safety of subcutaneous semaglutide 2.4mg weekly in people with obesity. STEP 1 — the pivotal trial — enrolled 1,961 adults with a BMI of 30 or above (or 27 with comorbidities) and demonstrated a mean weight reduction of 14.9% at 68 weeks, compared with 2.4% in the placebo group. Crucially, approximately one-third of participants achieved weight loss of 20% or more — a result that would have been considered extraordinary for any pharmacological intervention prior to this era.
STEP 4 addressed one of the most clinically important questions about long-term use: what happens when treatment is discontinued? Participants who continued semaglutide maintained their weight loss, whilst those who switched to placebo regained an average of 6.9% of body weight within 48 weeks — highlighting that, like many chronic disease treatments, GLP-1 therapy requires ongoing use to maintain its effects. This is not a failure of the drug; it is consistent with the understanding of obesity as a chronic, relapsing condition with an underlying biological aetiology.
Beyond Semaglutide: The GLP-1 Landscape
The success of semaglutide has catalysed an unprecedented wave of pharmaceutical development in the GLP-1 space. Every major pharmaceutical company with metabolic disease programmes now has one or more GLP-1 or multi-agonist compounds in development, and the pipeline of next-generation agents promises further improvements in efficacy, tolerability, and convenience. Here is a comprehensive overview of the current and near-future GLP-1 landscape for UK patients.
Tirzepatide (Mounjaro)
Currently the most effective approved weight management medication available in the UK. Mounjaro’s dual mechanism — activating both GIP and GLP-1 receptors — produces synergistic effects that exceed those of GLP-1 agonism alone. The SURMOUNT-1 trial demonstrated mean weight loss of 20.9% at 72 weeks with the 15mg dose, with one-third of participants achieving weight loss exceeding 25%. Approved by MHRA for weight management in November 2023. Private market availability has grown substantially throughout 2024–25.
MHRA Approved — UK
Oral Semaglutide (Rybelsus)
Rybelsus represents the first commercially available oral GLP-1 receptor agonist. Licensed for type 2 diabetes rather than weight management, oral semaglutide offers a needle-free alternative for patients who are unable or unwilling to self-inject. Bioavailability is lower than the injectable formulation, and the drug must be taken fasting with a small volume of water. Clinical development of higher-dose oral semaglutide formulations specifically for weight management is ongoing, with trials reporting promising results at 50mg doses.
Licensed — Diabetes (UK)
CagriSema
CagriSema combines semaglutide with cagrilintide, an analogue of the pancreatic hormone amylin. Amylin complements GLP-1 activity by slowing gastric emptying and reducing food intake through independent central pathways. Phase 3 trial results reported in late 2024 showed mean weight loss of approximately 22.7% — comparable to Mounjaro — with the combined agent appearing to produce more even weight loss distribution. Regulatory submission expected in 2025.
Phase 3 — Pipeline
Retatrutide
Retatrutide is a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data published in the New England Journal of Medicine demonstrated mean weight loss of 24.2% at 48 weeks — the largest weight loss ever reported in a Phase 2 trial. The addition of glucagon receptor agonism is thought to enhance energy expenditure as well as appetite suppression. Phase 3 development is progressing, though UK regulatory approval remains several years away.
Phase 3 — Pipeline
Oral GLP-1 Pipeline
The inconvenience of weekly injections has motivated significant pharmaceutical investment in oral GLP-1 formulations beyond Rybelsus. Pfizer’s danuglipron, Structure Therapeutics’ GSBR-1290, and Novo Nordisk’s high-dose oral semaglutide are all in active development. Orforglipron — a non-peptide GLP-1 receptor agonist that does not require food or water restrictions for absorption — has demonstrated meaningful weight loss in Phase 2 trials and may represent a significant convenience improvement over current oral options.
Phase 2 / Early Phase 3
Amycretin & Next-Gen Agents
Amycretin is a single-molecule combined GLP-1/amylin receptor agonist — distinct from CagriSema in that it is a unified molecule rather than a combination of two separate drugs. Early Phase 1 data presented in 2024 showed weight loss of up to 13.1% after just 12 weeks at the highest dose tested — a remarkable early signal. If these results replicate in larger trials, amycretin could represent the next step change in GLP-1 pharmacology. Multiple other next-generation agents with novel mechanisms are in earlier development stages.
Phase 1–2
Peptide Therapy Explained
Alongside the mainstream GLP-1 drug class, a parallel field of therapeutic peptide research has attracted considerable scientific and patient interest. Peptides — short chains of amino acids that function as biological signalling molecules — are found throughout the body, regulating everything from tissue repair and growth hormone secretion to inflammation and immune function. Research peptides are synthetic compounds designed to mimic, augment, or modulate these natural signalling molecules, with potential applications in recovery, inflammation, longevity, and body composition.
It is important to state clearly at the outset: the majority of research peptides discussed below are not licensed medicines in the UK. They do not have the same evidence base as approved pharmaceuticals, they have not undergone the clinical trial programmes required for regulatory approval, and their long-term safety profiles in humans are not well characterised. We present this information for educational purposes only, and patients should approach any use of unlicensed compounds with appropriate medical guidance and informed caution.
| Peptide | Primary Research Area | Evidence Level | UK Regulatory Status |
|---|---|---|---|
| BPC-157 (Body Protection Compound-157) | Tissue repair, gut healing, tendon and ligament recovery, neuroprotection | Extensive animal data; limited human studies. Strong pre-clinical signal for gastrointestinal healing. | Unlicensed. Not approved for human therapeutic use in UK. |
| TB-500 (Thymosin Beta-4 fragment) | Wound healing, anti-inflammatory, cardiac tissue repair, angiogenesis | Animal and in vitro evidence. Human thymosin beta-4 trials have occurred in cardiac and eye conditions; TB-500 specifically has limited human trial data. | Unlicensed. Research compound only. |
| CJC-1295 | Growth hormone secretagogue; muscle building, fat loss, sleep quality | Human Phase 1 and 2 data on GH pulse amplitude. Combination with Ipamorelin (DAC:GRF) is widely researched. | Unlicensed. Not approved for human therapeutic use. |
| Ipamorelin | Growth hormone-releasing peptide (GHRP); body composition, recovery | Human Phase 1 data showing selective GH secretion. Considered more selective and better-tolerated than older GHRPs. | Unlicensed. Research use only. |
| Epithalon | Telomere extension, anti-ageing, circadian rhythm regulation | Russian-origin research; some human longevity data. Evidence quality and reproducibility variable. | Unlicensed. Research compound only. |
| Selank / Semax | Anxiolytic, nootropic, neuroprotective; cognitive function | Russian clinical data. Licensed as medicines in Russia; no EMA or MHRA approval. | Unlicensed in UK. No approved therapeutic indication. |
Safety and Side Effects: An Evidence-Based Overview
GLP-1 receptor agonists have a well-characterised safety profile derived from large clinical trial programmes involving tens of thousands of participants. The most commonly reported side effects are gastrointestinal in nature, arising from the drug’s effect on gastric motility and the gut-brain axis. These are generally dose-dependent, most prominent during dose escalation, and diminish over time in the majority of patients.
Common Side Effects
Nausea is the most frequently reported adverse effect, affecting 44–50% of patients in the semaglutide STEP trials. It is typically mild to moderate, peaks during dose escalation periods, and resolves within the first 2–3 months of treatment at the maintenance dose. Vomiting occurs less frequently (approximately 24% in STEP 1) and responds to the same management strategies as nausea: eating smaller portions, avoiding high-fat foods, eating slowly, and not lying down immediately after meals. Diarrhoea (30%) and constipation (24%) are also commonly reported, often alternating. Fatigue and headache are reported in the early weeks of treatment.
Serious but Uncommon Risks
GLP-1 receptor agonists carry a boxed warning in some markets regarding a potential increased risk of medullary thyroid carcinoma, based on animal studies showing thyroid C-cell tumours in rodents at pharmacologically relevant concentrations. Human epidemiological studies have not confirmed this risk, but GLP-1 drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). Pancreatitis has been reported in patients taking GLP-1 drugs, and patients should seek immediate medical attention for persistent, severe abdominal pain. The causal relationship remains uncertain based on the available evidence, but it is a clinically important consideration.
Muscle Loss: An Important Consideration
An increasingly discussed concern with GLP-1-driven weight loss is the proportion of weight lost as lean mass rather than fat mass. Analyses of body composition data from GLP-1 trials suggest that approximately 25–40% of weight lost may be lean tissue — a figure higher than observed with diet and exercise alone. Preserving muscle mass through adequate protein intake (1.2–1.6g per kilogram of body weight is a commonly cited target) and regular resistance exercise is a clinically important adjunct to GLP-1 therapy that is not always communicated to patients by prescribers.
Diet, Exercise & Lifestyle: Practical Guidance for GLP-1 Users
GLP-1 receptor agonists are powerful tools, but they are not meant to function in isolation. The clinical trials that demonstrated their efficacy consistently incorporated behavioural support, dietary counselling, and encouragement of physical activity. Patients who combine GLP-1 therapy with intentional lifestyle changes consistently achieve better outcomes than those who rely on the medication alone. Here is what the evidence supports.
GLP-1 drugs reduce appetite non-selectively — patients eat less of everything. Consciously prioritising protein (lean meats, eggs, legumes, dairy) helps preserve muscle mass, supports satiety, and maintains metabolic rate. Target 1.2–1.6g of protein per kilogram of body weight daily. This often requires deliberate meal planning as appetite cues become less reliable.
The evidence for resistance exercise in preserving lean mass during GLP-1-driven weight loss is compelling. Even 2–3 sessions per week of moderate resistance training (bodyweight exercises, free weights, or resistance bands) can substantially reduce the proportion of weight lost as muscle tissue. It also supports metabolic health, bone density, and cardiovascular fitness.
Because GLP-1 drugs slow gastric emptying, high-fat meals can exacerbate nausea and gastrointestinal discomfort. Most patients find that smaller, more frequent meals with moderate fat content are better tolerated. Highly processed foods, carbonated drinks, and alcohol may worsen side effects and reduce the quality of weight loss achieved.
Adequate hydration is particularly important for GLP-1 users. Reduced appetite can lead to reduced fluid intake alongside food. Dehydration exacerbates headaches, fatigue, and constipation — all common early side effects. Aim for at least 2 litres of water daily, and more during warmer weather or physical activity.
Poor sleep independently drives weight regain and metabolic dysfunction. Sleep deprivation elevates ghrelin (the hunger hormone) and suppresses leptin (the satiety hormone) — partially counteracting the appetite-suppressive effects of GLP-1 therapy. Prioritising sleep hygiene is a meaningful but frequently overlooked component of any weight management programme.
Given the evidence from STEP 4 that weight is regained when GLP-1 therapy is discontinued, patients should discuss long-term treatment strategy with their prescriber before beginning. Understanding upfront that this is likely to be an ongoing management strategy — rather than a time-limited course — allows for more realistic expectations and better adherence.
Why Semaglutide Guide?
In a landscape saturated with commercially motivated content, we operate differently.
Peer-Reviewed Foundation
Every clinical claim is traceable to published research in peer-reviewed journals, authoritative regulatory guidance, or official NHS/NICE documentation. We cite sources consistently and transparently.
Commercially Independent
We do not accept sponsored content, paid placements, or affiliate relationships with pharmaceutical companies or weight loss clinics. Our operating model is designed to preserve editorial independence as an absolute priority.
Regularly Updated
The GLP-1 field moves faster than almost any other area of medicine. We update our guides within weeks of significant new trial results, regulatory decisions, or safety communications. Our publication dates are always visible.
Written by Clinicians
Our content team includes qualified pharmacists, a medical writer with specialist metabolic medicine experience, and a clinical advisory board with expertise in GLP-1 pharmacology and obesity medicine.
UK-Focused
We specifically cover UK licensing, NHS availability, MHRA guidance, and UK prescribing frameworks. We are aware that the US, European, and UK regulatory landscapes differ meaningfully, and we ensure our guidance reflects the UK context.
Patient-Centred Voice
Clinical accuracy does not require impenetrable language. We write for patients first, without talking down to them. Complex pharmacology is explained clearly. Uncertainty is acknowledged honestly. Practical implications are always surfaced.
Frequently Asked Questions
Both Ozempic and Wegovy contain the same active ingredient — semaglutide — and are manufactured by Novo Nordisk. The key differences are their licensed indications and approved doses. Ozempic is licensed for the treatment of type 2 diabetes and is available in doses of 0.5mg, 1mg, and 2mg weekly. Wegovy is licensed specifically for weight management and is available in a 2.4mg weekly dose, which is higher than the maximum Ozempic dose. In clinical practice, some prescribers have prescribed Ozempic off-label for weight management, particularly when Wegovy was unavailable due to supply constraints. This is a clinically accepted practice but means the specific weight management formulation — and its associated patient support materials — is not being used.
The STEP 1 trial, which is the pivotal clinical study for Wegovy, showed a mean weight reduction of 14.9% of body weight at 68 weeks in the active treatment group, compared with 2.4% in the placebo group. However, this is an average — individual responses vary considerably. Approximately one-third of STEP 1 participants achieved weight loss exceeding 20%, whilst a smaller proportion achieved less than 5%. Factors influencing response include genetics, adherence, diet quality, physical activity levels, and whether there are underlying metabolic conditions. Weight loss also tends to plateau as a new homeostatic setpoint is established, typically within 12–18 months of reaching the maintenance dose.
NHS access to Wegovy for weight management in England is currently limited and is being rolled out gradually through specialist weight management services. NICE approved Wegovy for use within NHS specialist weight management services in March 2023, subject to specific eligibility criteria — including a BMI of 35 or above with at least one weight-related comorbidity, or a BMI of 30–34.9 in high-risk groups. NHS England has also piloted its use through primary care in some areas. For most patients, access through the NHS currently requires a referral to a specialist service, which can involve waiting times. Private prescribing offers faster access but at considerably higher cost.
The evidence from the STEP 4 trial is clear: the majority of weight lost during semaglutide treatment is regained following discontinuation. In STEP 4, participants who discontinued semaglutide at week 20 and switched to placebo regained an average of 6.9% of body weight — representing approximately two-thirds of what had been lost — by week 68. This underscores the understanding of obesity as a chronic, relapsing biological condition rather than one that can be “cured” by a time-limited pharmacological intervention. Patients and prescribers should discuss long-term treatment strategy proactively, including whether ongoing therapy, dose maintenance, or lifestyle-based maintenance strategies can sustain outcomes after formal treatment ends.
Yes. Semaglutide (as Ozempic) was originally developed and licensed for the management of type 2 diabetes, where it is highly effective at improving glycaemic control and HbA1c, whilst also producing meaningful weight loss. People with type 2 diabetes who also have obesity may be candidates for Wegovy (2.4mg weekly) as a weight management treatment, depending on their specific clinical profile. If you have type 2 diabetes and are taking other glucose-lowering medications — particularly insulin or sulfonylureas — it is important that your prescriber reviews your regimen before starting a GLP-1 agonist, as dose adjustments may be required to avoid hypoglycaemia.
Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and approved by the MHRA for weight management in November 2023. It differs from semaglutide in that it activates both GIP and GLP-1 receptors, producing synergistic appetite-suppressive and metabolic effects that appear to exceed those of GLP-1 agonism alone. Head-to-head trial data is limited, but indirect comparisons of the SURMOUNT (tirzepatide) and STEP (semaglutide) programmes suggest that tirzepatide produces greater mean weight loss — approximately 20–22% versus 15% for semaglutide. Both drugs are well-tolerated, with broadly similar gastrointestinal side effect profiles. The choice between them typically comes down to individual patient factors, prescriber preference, availability, and cost.
The honest answer is that we do not yet know with confidence, because the human clinical trial data needed to answer this question simply does not exist in sufficient volume or quality. BPC-157 has demonstrated a compelling pre-clinical profile in animal models, with effects on gut healing, tendon repair, and neuroprotection that are reproducible and mechanistically plausible. However, translation from animal models to human clinical applications is notoriously unreliable in pharmacology — many compounds that look promising in animals fail in human trials. Until robust Phase 2 and Phase 3 human trial data is available, the safety and efficacy of BPC-157 in humans cannot be established to the standards required for clinical recommendation. We recommend discussing any interest in research peptides with a knowledgeable healthcare professional.
Every article and guide on Semaglutide Guide displays its publication date and most recent review date prominently. We have a systematic content review process that prioritises high-traffic and clinically important guides, with major updates triggered by significant new trial results, regulatory decisions (MHRA approvals or safety communications), NICE guideline updates, and changes to NHS prescribing policy. The GLP-1 space is particularly fast-moving, and we are committed to updating our most clinically important content within 4 weeks of significant new evidence publication. We also maintain a “Research Updates” section that tracks new publications on an ongoing basis.
The UK’s Most Rigorous GLP-1 Newsletter
Join over 12,000 patients, clinicians, and researchers who receive our fortnightly briefing on the latest GLP-1 and peptide research, regulatory developments, and clinical guidance. No sponsored content. No commercial bias. Just the evidence, clearly explained.